Aura Biosciences, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
Aura Biosciences executed a CEO transition on April 30, 2026: founder Elisabet de los Pinos terminated as CEO and transitioned to a 6-month consulting role with accelerated equity vesting; Natalie Holles hired as new CEO with $700k base salary, 55% bonus target, and ~2.5% equity grant (1.33M options + 367k RSUs) plus 0.5% performance-based RSUs. Simultaneously, the company repurchased up to 6.92M shares (from its $321M market cap) from investor Matrix Capital at the net public offering price, financed by a registered equity offering. The company also increased authorized common shares from 150M to 500M and extended option exercise periods to June 2028.
Why this rating
CEO succession and strategic buyback are material operational events. The $700k CEO salary and ~$20-25M implied equity grant (at typical biotech valuations) represent meaningful commitments. The 6.92M share repurchase (vs ~150M outstanding) is modest in % but tied to capital raise, and the 3.5x authorized share increase indicates runway for future financing. No revenue/product impact disclosed, so neutral on direction.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.